<?xml version='1.0' encoding='utf-8'?>
<document id="29595123"><sentence text="Investigation of a potential drug-drug interaction between salbutamol and ambroxol and bioequivalence of a new fixed-dose combination containing these two drugs in healthy Chinese subjects."><entity charOffset="59-69" id="DDI-PubMed.29595123.s1.e0" text="salbutamol" /><entity charOffset="74-82" id="DDI-PubMed.29595123.s1.e1" text="ambroxol" /><pair ddi="false" e1="DDI-PubMed.29595123.s1.e0" e2="DDI-PubMed.29595123.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29595123.s1.e0" e2="DDI-PubMed.29595123.s1.e1" /></sentence><sentence text="The aims of the study were to investigate the potential drug-drug interaction between salbutamol and ambroxol, the bioequivalence of the new fixed-dose combination containing salbutamol and ambroxol compared with co-administration of the two separate formulations, and to describe the safety and tolerability of the fixed-dose combination formulation in healthy Chinese volunteers"><entity charOffset="86-96" id="DDI-PubMed.29595123.s2.e0" text="salbutamol" /><entity charOffset="101-109" id="DDI-PubMed.29595123.s2.e1" text="ambroxol" /><entity charOffset="175-185" id="DDI-PubMed.29595123.s2.e2" text="salbutamol" /><entity charOffset="190-198" id="DDI-PubMed.29595123.s2.e3" text="ambroxol" /><pair ddi="false" e1="DDI-PubMed.29595123.s2.e0" e2="DDI-PubMed.29595123.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29595123.s2.e0" e2="DDI-PubMed.29595123.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29595123.s2.e0" e2="DDI-PubMed.29595123.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29595123.s2.e0" e2="DDI-PubMed.29595123.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29595123.s2.e1" e2="DDI-PubMed.29595123.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29595123.s2.e1" e2="DDI-PubMed.29595123.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29595123.s2.e1" e2="DDI-PubMed.29595123.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29595123.s2.e2" e2="DDI-PubMed.29595123.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29595123.s2.e2" e2="DDI-PubMed.29595123.s2.e3" /></sentence><sentence text="" /><sentence text="An open-label, single-dose, four-treatment, four-period crossover study for evaluation of drug-drug interaction and bioequivalence (n = 24) was performed" /><sentence text=" Each participant received salbutamol 4 mg, ambroxol 15 mg, salbutamol 4 mg co-administered with ambroxol 15 mg or fixed-dose combination formulation (salbutamol 4 mg and ambroxol 15 mg)"><entity charOffset="27-37" id="DDI-PubMed.29595123.s5.e0" text="salbutamol" /><entity charOffset="44-52" id="DDI-PubMed.29595123.s5.e1" text="ambroxol" /><entity charOffset="60-70" id="DDI-PubMed.29595123.s5.e2" text="salbutamol" /><entity charOffset="97-105" id="DDI-PubMed.29595123.s5.e3" text="ambroxol" /><entity charOffset="151-161" id="DDI-PubMed.29595123.s5.e4" text="salbutamol" /><entity charOffset="171-179" id="DDI-PubMed.29595123.s5.e5" text="ambroxol" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e0" e2="DDI-PubMed.29595123.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e0" e2="DDI-PubMed.29595123.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e0" e2="DDI-PubMed.29595123.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e0" e2="DDI-PubMed.29595123.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e0" e2="DDI-PubMed.29595123.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e0" e2="DDI-PubMed.29595123.s5.e5" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e1" e2="DDI-PubMed.29595123.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e1" e2="DDI-PubMed.29595123.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e1" e2="DDI-PubMed.29595123.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e1" e2="DDI-PubMed.29595123.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e1" e2="DDI-PubMed.29595123.s5.e5" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e2" e2="DDI-PubMed.29595123.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e2" e2="DDI-PubMed.29595123.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e2" e2="DDI-PubMed.29595123.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e2" e2="DDI-PubMed.29595123.s5.e5" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e3" e2="DDI-PubMed.29595123.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e3" e2="DDI-PubMed.29595123.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e3" e2="DDI-PubMed.29595123.s5.e5" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e4" e2="DDI-PubMed.29595123.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29595123.s5.e4" e2="DDI-PubMed.29595123.s5.e5" /></sentence><sentence text=" Plasma concentrations of two analytes were determined with the use of validated LC-MS/MS method" /><sentence text=" Safety and tolerability were assessed by recording adverse events" /><sentence text="" /><sentence text="Co-administration of salbutamol and ambroxol was not associated with a significant influence on single salbutamol or ambroxol pharmacokinetics"><entity charOffset="21-31" id="DDI-PubMed.29595123.s9.e0" text="salbutamol" /><entity charOffset="36-44" id="DDI-PubMed.29595123.s9.e1" text="ambroxol" /><entity charOffset="103-113" id="DDI-PubMed.29595123.s9.e2" text="salbutamol" /><entity charOffset="117-125" id="DDI-PubMed.29595123.s9.e3" text="ambroxol" /><pair ddi="false" e1="DDI-PubMed.29595123.s9.e0" e2="DDI-PubMed.29595123.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29595123.s9.e0" e2="DDI-PubMed.29595123.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29595123.s9.e0" e2="DDI-PubMed.29595123.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29595123.s9.e0" e2="DDI-PubMed.29595123.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29595123.s9.e1" e2="DDI-PubMed.29595123.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29595123.s9.e1" e2="DDI-PubMed.29595123.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29595123.s9.e1" e2="DDI-PubMed.29595123.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29595123.s9.e2" e2="DDI-PubMed.29595123.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29595123.s9.e2" e2="DDI-PubMed.29595123.s9.e3" /></sentence><sentence text=" After statistical comparisons of log-transformed C&lt;sub&gt;max&lt;/sub&gt; and AUC of salbutamol and ambroxol between fixed-dose combination and concomitant treatments, all 90% confidence intervals of geometric mean ratios were within the predefined equivalence range of 80 - 125%"><entity charOffset="77-87" id="DDI-PubMed.29595123.s10.e0" text="salbutamol" /><entity charOffset="92-100" id="DDI-PubMed.29595123.s10.e1" text="ambroxol" /><pair ddi="false" e1="DDI-PubMed.29595123.s10.e0" e2="DDI-PubMed.29595123.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29595123.s10.e0" e2="DDI-PubMed.29595123.s10.e1" /></sentence><sentence text=" No serious adverse events were reported, and all treatments were safe and well tolerated in Chinese healthy subjects" /><sentence text="" /><sentence text="There were no significant drug-drug pharmacokinetic interactions between salbutamol and ambroxol after oral administration"><entity charOffset="73-83" id="DDI-PubMed.29595123.s13.e0" text="salbutamol" /><entity charOffset="88-96" id="DDI-PubMed.29595123.s13.e1" text="ambroxol" /><pair ddi="false" e1="DDI-PubMed.29595123.s13.e0" e2="DDI-PubMed.29595123.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29595123.s13.e0" e2="DDI-PubMed.29595123.s13.e1" /></sentence><sentence text=" The new formulation was bioequivalent to the co-administration of two drugs in separate dosage forms" /><sentence text=" " /><sentence text="" /></document>